Rajan Sharma
Stock Analyst at Goldman Sachs
(2.40)
# 2,924
Out of 4,649 analysts
202
Total ratings
49.1%
Success rate
1.4%
Average return
Main Sectors:
Stocks Rated by Rajan Sharma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AUTL Autolus Therapeutics | Rated: Buy | $5.7 → $5.8 | $2.15 | +169.77% | 6 | Aug 11, 2026 | |
| BCAX Bicara Therapeutics | Rated: Hold | $20 | $24.28 | -17.63% | 1 | Aug 11, 2026 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | kr 2,350 → kr 216.74 | kr 2,027 | -89.31% | 7 | Aug 7, 2026 | |
| IMCR Immunocore Holdings | Maintained: Buy | $73 → $74 | $34.21 | +116.31% | 13 | Aug 6, 2026 | |
| LON: 0NZT UCB SA | Maintained: Buy | €299.00 → €295.00 | €215.55 | +36.86% | 8 | Aug 3, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 16,370p → 16,070p | 11,460p | +40.23% | 41 | Jul 28, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | 1,890p | 1,818p | +3.99% | 31 | Jul 28, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | €885.00 → €907.00 | €730.50 | +24.16% | 17 | Jul 24, 2026 | |
| IMTX Immatics | Rated: Buy | $11 → $12 | $9.44 | +29.24% | 4 | May 12, 2026 | |
| GMAB Genmab | Upgraded: Buy | $26 → $31 | $31.94 | -4.51% | 4 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $7.5 → $4.9 | $7.13 | -31.28% | 5 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $7.25 → $5.81 | $14.02 | -58.56% | 3 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Sell | €1.30 → €1.01 | €2.37 | -57.31% | 5 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | €25.00 → €18.00 | €23.30 | -22.75% | 8 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $813 → $910 | $851.29 | +6.90% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.20 | - | 1 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.86 | - | 5 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $45 | $76.75 | n/a | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €2.85 → €3.30 | €3.00 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $98.66 | n/a | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $157 → $171 | $52.68 | n/a | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 2.00 | CHF 5.92 | n/a | 8 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $47 | $49.52 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $122.44 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $36.20 | n/a | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €90.00 → €100.00 | €156.00 | n/a | 6 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €44.00 | €52.50 | n/a | 7 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $20 | $12.20 | n/a | 2 | May 4, 2022 |
Autolus Therapeutics
Aug 11, 2026
Rated: Buy
Price Target: $5.7 → $5.8
Current: $2.15
Upside: +169.77%
Bicara Therapeutics
Aug 11, 2026
Rated: Hold
Price Target: $20
Current: $24.28
Upside: -17.63%
Genmab A/S
Aug 7, 2026
Maintained: Buy
Price Target: kr 2,350 → kr 216.74
Current: kr 2,027
Upside: -89.31%
Immunocore Holdings
Aug 6, 2026
Maintained: Buy
Price Target: $73 → $74
Current: $34.21
Upside: +116.31%
UCB SA
Aug 3, 2026
Maintained: Buy
Price Target: €299.00 → €295.00
Current: €215.55
Upside: +36.86%
AstraZeneca PLC
Jul 28, 2026
Maintained: Buy
Price Target: 16,370p → 16,070p
Current: 11,460p
Upside: +40.23%
GSK plc
Jul 28, 2026
Maintained: Hold
Price Target: 1,890p
Current: 1,818p
Upside: +3.99%
argenx SE
Jul 24, 2026
Maintained: Buy
Price Target: €885.00 → €907.00
Current: €730.50
Upside: +24.16%
Immatics
May 12, 2026
Rated: Buy
Price Target: $11 → $12
Current: $9.44
Upside: +29.24%
Genmab
Apr 22, 2026
Upgraded: Buy
Price Target: $26 → $31
Current: $31.94
Upside: -4.51%
Apr 22, 2026
Downgraded: Sell
Price Target: $7.5 → $4.9
Current: $7.13
Upside: -31.28%
Apr 9, 2026
Maintained: Sell
Price Target: $7.25 → $5.81
Current: $14.02
Upside: -58.56%
Apr 9, 2026
Rated: Sell
Price Target: €1.30 → €1.01
Current: €2.37
Upside: -57.31%
Apr 9, 2026
Rated: Hold
Price Target: €25.00 → €18.00
Current: €23.30
Upside: -22.75%
Feb 26, 2026
Maintained: Buy
Price Target: $813 → $910
Current: $851.29
Upside: +6.90%
Feb 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.20
Upside: -
Jan 9, 2026
Rated: Hold
Price Target: n/a
Current: $1.86
Upside: -
Jul 30, 2025
Maintained: Buy
Price Target: $35 → $45
Current: $76.75
Upside: n/a
Mar 21, 2025
Maintained: Hold
Price Target: €2.85 → €3.30
Current: €3.00
Upside: n/a
Oct 3, 2024
Maintained: Hold
Price Target: n/a
Current: $98.66
Upside: n/a
Aug 16, 2024
Maintained: Buy
Price Target: $157 → $171
Current: $52.68
Upside: n/a
Jul 30, 2024
Maintained: Hold
Price Target: CHF 2.00
Current: CHF 5.92
Upside: n/a
May 30, 2024
Initiated Coverage: Hold
Price Target: $47
Current: $49.52
Upside: n/a
May 30, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $122.44
Upside: n/a
Dec 20, 2023
Maintained: Buy
Price Target: n/a
Current: $36.20
Upside: n/a
Feb 13, 2023
Maintained: Hold
Price Target: €90.00 → €100.00
Current: €156.00
Upside: n/a
May 16, 2022
Maintained: Hold
Price Target: €44.00
Current: €52.50
Upside: n/a
May 4, 2022
Downgraded: Hold
Price Target: $40 → $20
Current: $12.20
Upside: n/a